| pubmed-article:9571984 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9571984 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:9571984 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:9571984 | lifeskim:mentions | umls-concept:C0205070 | lld:lifeskim |
| pubmed-article:9571984 | lifeskim:mentions | umls-concept:C0405581 | lld:lifeskim |
| pubmed-article:9571984 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:9571984 | lifeskim:mentions | umls-concept:C0025513 | lld:lifeskim |
| pubmed-article:9571984 | lifeskim:mentions | umls-concept:C0066691 | lld:lifeskim |
| pubmed-article:9571984 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9571984 | pubmed:dateCreated | 1998-5-21 | lld:pubmed |
| pubmed-article:9571984 | pubmed:abstractText | Molinate is a thiocarbamate herbicide widely used in rice culture. Studies conducted for regulatory purposes have indicated that molinate exposure causes male reproductive damage in rats. The present study describes the testicular lesion after administration of single doses of molinate. The hypothesis that a metabolite of molinate is responsible for testicular toxicity was also investigated. Testicular damage was evaluated histopathologically in Sprague-Dawley rats 48 h and 1, 2, and 3 weeks after administration of molinate (100-400 mg/kg i.p.). No testicular damage was seen at any time point at the 100 mg/kg dose level. Damage was first seen 1 week after 200 mg/kg and 48 h after 400 mg/kg. The lesion was characterized by Sertoli cell vacuolation, failed spermiation, and phagocytosis of spermatids particularly evident at Stages X and XI. With increasing time, damage progressed until disorganization of the seminiferous epithelium was extensive, multinucleated giant cells were numerous, and neither spermatozoa nor late step spermatids were present. At 3 weeks after administration of the two higher-dose levels, germ cells in the seminiferous tubules were almost completely absent. Administration of the sulfoxide metabolite of molinate (200 mg/kg i.p.) caused testicular damage similar in severity to that seen at the 400 mg/kg dose level for the parent compound, indicating that it was more potent as a testicular toxicant. In vitro metabolism studies using liver and testis microsomes found that the major metabolite in both preparations was molinate sulfoxide. Testis microsomes produced only slightly less sulfoxide when compared with liver microsomes. Molinate was also metabolized via ring hydroxylation to form small amounts of hydroxymolinate. The amount of hydroxymolinate was substantially less in testis microsomes. Overall, these data indicate that sulfoxidation of molinate plays a role in molinat-induced testicular toxicity. Moreover, molinate is metabolized readily by both liver and testis microsomal enzymes, suggesting that the molinate toxic metabolite could be formed in the testis in close proximity to its site of action. | lld:pubmed |
| pubmed-article:9571984 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9571984 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9571984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9571984 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9571984 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:9571984 | pubmed:issn | 0041-008X | lld:pubmed |
| pubmed-article:9571984 | pubmed:author | pubmed-author:HessR ARA | lld:pubmed |
| pubmed-article:9571984 | pubmed:author | pubmed-author:MillerM GMG | lld:pubmed |
| pubmed-article:9571984 | pubmed:author | pubmed-author:JewellW TWT | lld:pubmed |
| pubmed-article:9571984 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9571984 | pubmed:volume | 149 | lld:pubmed |
| pubmed-article:9571984 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9571984 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9571984 | pubmed:pagination | 159-66 | lld:pubmed |
| pubmed-article:9571984 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:meshHeading | pubmed-meshheading:9571984-... | lld:pubmed |
| pubmed-article:9571984 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9571984 | pubmed:articleTitle | Testicular toxicity of molinate in the rat: metabolic activation via sulfoxidation. | lld:pubmed |
| pubmed-article:9571984 | pubmed:affiliation | Department of Environmental Toxicology, University of California, Davis 95616, USA. | lld:pubmed |
| pubmed-article:9571984 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9571984 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:9571984 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9571984 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9571984 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9571984 | lld:pubmed |
